Patrick J. Stiff

26.2k total citations · 5 hit papers
247 papers, 8.4k citations indexed

About

Patrick J. Stiff is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Patrick J. Stiff has authored 247 papers receiving a total of 8.4k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Oncology, 120 papers in Hematology and 69 papers in Pathology and Forensic Medicine. Recurrent topics in Patrick J. Stiff's work include Hematopoietic Stem Cell Transplantation (84 papers), Lymphoma Diagnosis and Treatment (64 papers) and Acute Myeloid Leukemia Research (35 papers). Patrick J. Stiff is often cited by papers focused on Hematopoietic Stem Cell Transplantation (84 papers), Lymphoma Diagnosis and Treatment (64 papers) and Acute Myeloid Leukemia Research (35 papers). Patrick J. Stiff collaborates with scholars based in United States, Canada and Italy. Patrick J. Stiff's co-authors include Auayporn Nademanee, Ivana N. Micallef, John F. DiPersio, Richard T. Maziarz, Gary Bridger, Tawee Tanvetyanon, John M. McCarty, Brian J. Bolwell, Gary Calandra and Richard I. Fisher and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Patrick J. Stiff

236 papers receiving 8.2k citations

Hit Papers

Palifermin for Oral Mucos... 2004 2026 2011 2018 2004 2009 2009 2015 2013 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers
    2004 606 citations Patrick J. Stiff, Daniel J. Weisdorf et al. profile →
  2. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
    2009 579 citations John F. DiPersio, Auayporn Nademanee et al. Blood profile →
  3. Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma
    2009 512 citations John F. DiPersio, Ivana N. Micallef et al. Journal of Clinical Oncology profile →
  4. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
    2015 477 citations Auayporn Nademanee, Patrick J. Stiff et al. profile →
  5. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
    2013 460 citations Patrick J. Stiff et al. Blood profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Patrick J. Stiff 4.1k 3.2k 2.3k 1.4k 1.4k 247 8.4k
Marco Bregni 4.7k 1.1× 3.8k 1.2× 3.0k 1.3× 836 0.6× 2.0k 1.4× 193 10.0k
Anne Kessinger 3.0k 0.7× 3.3k 1.0× 2.1k 0.9× 1.0k 0.7× 767 0.6× 213 7.4k
Gregor Verhoef 3.0k 0.7× 3.1k 1.0× 3.5k 1.5× 1.0k 0.7× 2.2k 1.6× 187 9.4k
Gary Spitzer 3.0k 0.7× 3.3k 1.0× 1.6k 0.7× 943 0.7× 1.3k 1.0× 219 7.3k
David J. Inwards 3.8k 0.9× 1.9k 0.6× 4.4k 1.9× 865 0.6× 1.3k 1.0× 265 8.0k
Auayporn Nademanee 3.3k 0.8× 3.1k 1.0× 3.2k 1.4× 535 0.4× 603 0.4× 180 7.3k
Chitra Hosing 3.2k 0.8× 5.1k 1.6× 1.8k 0.8× 516 0.4× 1.3k 1.0× 372 8.9k
D. Crowther 4.7k 1.1× 1.5k 0.5× 3.2k 1.4× 2.0k 1.4× 1.2k 0.9× 178 9.3k
Philip J. Bierman 3.2k 0.8× 1.6k 0.5× 3.9k 1.6× 683 0.5× 557 0.4× 210 6.5k
André Bosly 4.8k 1.2× 2.0k 0.6× 5.8k 2.5× 987 0.7× 1.4k 1.0× 191 9.7k

Countries citing papers authored by Patrick J. Stiff

Since Specialization
Citations

This map shows the geographic impact of Patrick J. Stiff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick J. Stiff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick J. Stiff more than expected).

Fields of papers citing papers by Patrick J. Stiff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick J. Stiff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick J. Stiff. The network helps show where Patrick J. Stiff may publish in the future.

Co-authorship network of co-authors of Patrick J. Stiff

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick J. Stiff. A scholar is included among the top collaborators of Patrick J. Stiff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick J. Stiff. Patrick J. Stiff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Horwitz, Mitchell E., Gary J. Schiller, Sang‐Bing Tsai, et al.. (2025). Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program. Transplantation and Cellular Therapy. 31(7). 436–447.
2.
Oluwole, Olalekan O., Armin Ghobadi, Ryan D. Cassaday, et al.. (2024). Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.. Journal of Clinical Oncology. 42(16_suppl). 6531–6531. 3 indexed citations
3.
Stiff, Patrick J.. (2024). Cabozantinib inhibits tumor growth in mice with ovarian cancer. American Journal of Cancer Research. 14(10). 4788–4802.
4.
Stiff, Patrick J., et al.. (2023). Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice. Cancers. 15(18). 4541–4541. 4 indexed citations
5.
Minter, Lisa M., Anne I. Sperling, Phong T. Le, et al.. (2023). Exopolysaccharide-Treated Dendritic Cells Effectively Ameliorate Acute Graft-versus-Host Disease. Transplantation and Cellular Therapy. 30(1). 79.e1–79.e10. 2 indexed citations
6.
Szabolcs, Paul, Roei David Mazor, Dima Yackoubov, et al.. (2023). Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy. Transplantation and Cellular Therapy. 29(8). 517.e1–517.e12. 6 indexed citations
7.
Hess, Brian, Nasheed Hossain, Volkan Beylergil, et al.. (2023). SWOG 2114: A RANDOMIZED PHASE II TRIAL OF CONSOLIDATION THERAPY FOLLOWING CD19 CAR T‐CELL TREATMENT FOR RELAPSED/REFRACTORY LARGE B‐CELL OR GRADE IIIB FOLLICULAR LYMPHOMA. Hematological Oncology. 41(S2). 839–840. 3 indexed citations
8.
Mumby, Patricia, William Adams, Scott E. Smith, Murali Rao, & Patrick J. Stiff. (2023). Pharmacotherapy for the Prevention of Depression and Behavioral Side Effects in Hematopoietic Stem Cell Transplantation Patients. Transplantation and Cellular Therapy. 30(3). 320.e1–320.e11. 1 indexed citations
9.
Horwitz, Mitchell E., Sang‐Bing Tsai, Andrew R. Rezvani, et al.. (2023). Omidubicel-Onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies: Results of a Multicenter Open Label Expanded Access Program. Blood. 142(Supplement 1). 6894–6894.
10.
11.
Lin, Chenyu, Gautam Sajeev, Patrick J. Stiff, et al.. (2022). Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood. Transplantation and Cellular Therapy. 29(1). 52.e1–52.e9. 3 indexed citations
12.
Koning, Coco de, Weiyang Tao, Mitchell E. Horwitz, et al.. (2021). Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. Bone Marrow Transplantation. 56(11). 2826–2833. 3 indexed citations
13.
14.
Hong, Fangxin, Thomas M. Habermann, Leo I. Gordon, et al.. (2014). The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Annals of Oncology. 25(3). 669–674. 38 indexed citations
15.
16.
Beaudette-Zlatanova, Britte, Katherine L. Knight, Shubin Zhang, et al.. (2011). A human thymic epithelial cell culture system for the promotion of lymphopoiesis from hematopoietic stem cells. Experimental Hematology. 39(5). 570–579. 16 indexed citations
17.
DiPersio, John F., Ivana N. Micallef, Patrick J. Stiff, et al.. (2009). Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 27(28). 4767–4773. 512 indexed citations breakdown →
18.
Ueno, Naoto T., J. Douglas Rizzo, Taner Demirer, et al.. (2007). Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplantation. 41(6). 537–545. 47 indexed citations
19.
Leonard, John P., Jonathan W. Friedberg, Anas Younes, et al.. (2007). A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Annals of Oncology. 18(7). 1216–1223. 87 indexed citations
20.
Stiff, Patrick J., Philip L. McCarthy, Margarida Magalhaes‐Silverman, et al.. (2005). AMD3100 plus G-CSF rapidly mobilizes hematopoietic progenitor cells in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM), including those traditionally considered “poor mobilizers”. Biology of Blood and Marrow Transplantation. 11(2). 92–92. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marco Bregni Breakdown of academic impact, for papers by Anne Kessinger Breakdown of academic impact, for papers by Gregor Verhoef Breakdown of academic impact, for papers by Gary Spitzer Breakdown of academic impact, for papers by David J. Inwards Breakdown of academic impact, for papers by Auayporn Nademanee Breakdown of academic impact, for papers by Chitra Hosing Breakdown of academic impact, for papers by D. Crowther Breakdown of academic impact, for papers by Philip J. Bierman Breakdown of academic impact, for papers by André Bosly
Rankless by CCL
2026